肿瘤细胞治疗研究
英文原题：Beyond youth: Understanding CAR T cell fitness in the context of immunological aging.
Beyond youth: Understanding CAR T cell fitness in the context of immunological aging.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这一现象源于医学进步使寿命延长，美国人口中 20% 即将超过 65 岁。
人口老龄化是全球普遍的人口趋势，预计将给各国卫生和社会系统带来挑战。这一趋势源于医学进步延长了寿命，美国65岁以上人口占比不久将达到20%，与年龄相关疾病也将随之增加。衰老的特征是分子和细胞层面的生物维持能力及稳态丧失，与年龄相关表型变化相关，也可能直接导致这些变化。免疫系统衰退是衰老过程中的关键因素，而癌症是老年人群的主要死因之一。CAR-T 细胞疗法是一种创新治疗方法，主要在儿童和年轻成人血液肿瘤中取得成功；但对老年人常见疾病，例如高龄B细胞恶性肿瘤及大多数实体瘤适应证，其疗效仍普遍有限。其原因在于CAR-T 疗效高度依赖患者来源起始T细胞材料的适能。多项研究提示，T细胞衰老可能是CAR-T 功能不足的重要驱动因素。本文综述与良好CAR-T 结局相关的因素及其潜在机制，并探讨实验性和临床可行的T细胞年轻化策略。
Population aging, a pervasive global demographic trend, is anticipated to challenge health and social systems worldwide. This phenomenon is due to medical advancements enabling longer lifespans, with 20% of the US population soon to be over 65 years old. Consequently, there will be a surge in age-related diseases. Senescence, characterized by the loss of biological maintenance and homeostasis at molecular and cellular levels, either correlates with or directly causes age-related phenotypic changes. Decline of the immune system is a critical factor in the senescence process, with cancer being a primary cause of death in elderly populations. Chimeric antigen receptor (CAR) T cell therapy, an innovative approach, has demonstrated success mainly in pediatric and young adult hematological malignancies but remains largely ineffective for diseases affecting older populations, such as late-in-life B cell malignancies and most solid tumor indications. This limitation arises because CAR T cell efficacy heavily relies on the fitness of the patient-derived starting T cell material. Numerous studies suggest that T cell senescence may be a key driver of CAR T cell deficiency. This review examines correlates and underlying factors associated with favorable CAR T cell outcomes and explores potential experimental and clinically actionable strategies for T cell rejuvenation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
